INDP

Indaptus Therapeutics Inc

Jun 15 • 04:00PM ET

3.69

+0.11 3.07 %

Healthcare • Biotechnology • USA • Small • NASD

Peers: ARTV AVXL NGEN ACIU GLSI PALI PRLD RZLT TARA IMRX

Index	-	P/E	-	EPS (ttm)	-16.05	Insider Own	96.94%	Shs Outstand	113.24M	Perf Week	75.71%
Market Cap	417.86M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	3.46M	Perf Month	110.86%
Enterprise Value	416.36M	PEG	-	EPS next Q	-	Inst Own	0.07%	Short Float	0.50%	Perf Quarter	110.86%
Income	-18.86M	P/S	-	EPS this Y	-	Inst Trans	61.45%	Short Ratio	0.02	Perf Half Y	43.58%
Sales	0.00M	P/B	334.85	EPS next Y	-	ROA	-496.74%	Short Interest	0.02M	Perf YTD	26.80%
Book/sh	0.01	P/C	278.57	EPS next 5Y	-	ROE	-931.79%	52W High	19.91 -81.47%	Perf Year	-59.43%
Cash/sh	0.01	P/FCF	-	EPS past 3/5Y	23.68% 36.34%	ROIC	-1511.20%	52W Low	0.92 301.09%	Perf 3Y	-93.28%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	32.53% 36.10%	Perf 5Y	-99.16%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	61.43%	Oper. Margin	-	ATR (14)	0.77	Perf 10Y	-99.96%
Dividend Ex-Date	-	Quick Ratio	2.34	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	61.14	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.34	EPS Q/Q	97.42%	SMA20	67.56%	Beta	1.12	Target Price	10.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	57.85%	Rel Volume	0.40	Prev Close	3.58
Employees	5	LT Debt/Eq	0.00	Earnings	May 15 BMO	SMA200	43.99%	Avg Volume	951.39K	Price	3.69
IPO	Dec 26, 2012	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	378,878	Change	3.07%

May-15-26 07:00AM	Indaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire) -9.14%
Dec-29-25 07:00AM	Indaptus Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar (GlobeNewswire) +6.67%
Nov-17-25 08:00AM	Indaptus Therapeutics Chief Scientific Officer Dr. Michael Newman to Present at the Donor Selection & Cell Source Summit (GlobeNewswire) -9.56%
Nov-12-25 08:30AM	Indaptus Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) +6.25%
Sep-04-25 04:01PM	Indaptus Therapeutics Provides Clinical Update (GlobeNewswire) -14.63% -28.35%
04:05PM	Loading…
Sep-02-25 04:05PM	Indaptus Therapeutics to Present at the H.C. Wainwright 27?? Annual Global Investment Conference (GlobeNewswire) -5.34% -12.24%
Aug-13-25 08:00AM	Indaptus Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-01-25 08:14AM	Indaptus Therapeutics, Inc. Announces Additional Sale of $3.4 Million in Private Placement of Convertible Notes and Warrants (GlobeNewswire) +5.89%
Jun-25-25 07:00AM	Indaptus Therapeutics Announces Reverse Stock Split (GlobeNewswire) -18.29%
Jun-24-25 12:52PM	Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices (PR Newswire) -9.92%
Jun-13-25 08:00AM	Indaptus Therapeutics, Inc. Announces Sale of $2.3 Million in Private Placement of Convertible Notes and Warrants (GlobeNewswire)
Jun-02-25 08:00AM	Indaptus Therapeutics Doses First Patient in Phase 1b/2 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab (GlobeNewswire)
May-14-25 08:00AM	Indaptus Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
May-08-25 08:00AM	Indaptus Therapeutics Founder and Chief Scientific Officer Dr. Michael Newman Named Chair and Expert Speaker at 6th Annual Cytokine-Based Drug Development Summit (GlobeNewswire)
Mar-25-25 08:00AM	Indaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 Summit (GlobeNewswire) +7.96%
08:00AM	Loading…
Mar-20-25 08:00AM	Indaptus Therapeutics Reports New Data Demonstrating Successful Broad Immune System Activation in Weekly Dosing Trial of Decoy20 (GlobeNewswire)
Mar-18-25 08:00AM	Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab (GlobeNewswire)
Mar-13-25 07:30AM	Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-12-25 04:15PM	Registration Is Now Open For Tribe Public's Webinar Event Keys To The Kingdom: Unlocking The Power Of Your Immune System Featuring Indaptus Therapeutics' CEO On Monday, March 17, 2025 (GlobeNewswire)
Mar-04-25 08:00AM	Indaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening its Intellectual Property for Infectious Disease and Cancer Treatments (GlobeNewswire)
Feb-25-25 08:00AM	Indaptus Therapeutics' Chief Scientific Officer Dr. Michael Newman to Present at the 10th Annual Innate Killer Summit (GlobeNewswire)
Feb-05-25 08:00AM	Indaptus Therapeutics Receives Approval from Health Canada to Expand Clinical Trial of Decoy20 (GlobeNewswire) -9.49%
Jan-13-25 08:00AM	Indaptus Therapeutics, Inc. Announces $2.25 Million Private Placement Priced At-The-Market Under Nasdaq Rules (GlobeNewswire)
Jan-08-25 08:00AM	Indaptus Therapeutics Provides Year-End Review and Outlook for 2025 (GlobeNewswire)
Nov-22-24 08:36AM	Indaptus Therapeutics, Inc. Announces $2.135 Million Registered Direct Offering and Concurrent Private Placement (GlobeNewswire)
Nov-12-24 08:00AM	Indaptus Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-11-24 08:00AM	Indaptus Therapeutics' Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in Immunology (GlobeNewswire)
Nov-07-24 08:00AM	Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting (GlobeNewswire)
Oct-23-24 08:00AM	Indaptus Therapeutics to Present at Two Upcoming Investor Conferences (GlobeNewswire) -11.40%
Oct-22-24 08:00AM	Indaptus Therapeutics Announces Clinical Supply Agreement with BeiGene to Evaluate Novel Cancer Treatment Combinations (GlobeNewswire) +29.76%
08:00AM	Loading…
Oct-15-24 08:00AM	Indaptus Therapeutics Initiates Unrestricted Enrollment of Patients on Decoy20 Weekly Dosing Based on Encouraging Safety Data (GlobeNewswire)
Oct-10-24 08:00AM	Indaptus Therapeutics Founder and Chief Scientific Officer to Speak on Lumanity Webinar about the Future of Innate Immunity in Cancer Immunotherapy (GlobeNewswire)
Oct-08-24 08:00AM	Indaptus Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit (GlobeNewswire)
Sep-05-24 08:30AM	Indaptus Therapeutics Reports Encouraging New Safety Data for Decoy20 Clinical Program; Company Expands Enrollment of Patients on Weekly Dosing at Two Different Doses (GlobeNewswire)
Sep-03-24 08:00AM	Indaptus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-12-24 08:00AM	Indaptus Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-07-24 07:00AM	Indaptus Therapeutics, Inc. Announces $3.0 Million Registered Direct Offering and Concurrent Private Placement (GlobeNewswire)
Jun-11-24 08:00AM	Indaptus Therapeutics to Present Positive Data on Lead Product Candidate, Decoy20, at STING & TLR-Targeted Therapies Summit (GlobeNewswire)
Jun-04-24 08:00AM	Indaptus Therapeutics to Present New Positive Data on Decoy20 at Next-Gen Immuno-Oncology Conference (GlobeNewswire)
Jun-03-24 08:00AM	Indaptus Therapeutics Announces New Positive Data from Ongoing Phase 1 Trial of Decoy20 (GlobeNewswire) +18.14%
May-30-24 08:00AM	Indaptus Therapeutics to Present at the Jefferies Global Healthcare Conference (GlobeNewswire) -10.14%
May-29-24 08:00AM	Indaptus Therapeutics to Present New Cohort Data Confirming Original Pulse-Prime Hypothesis Via Phase 1 Clinical Trial of Decoy20 at the American Society of Clinical Oncology Annual Meeting (GlobeNewswire) +12.20%
May-22-24 08:00AM	Indaptus Therapeutics Announces Completion of First Patient to Receive Multiple Doses of Decoy20, the Company's Broad-Based, Pulse-Prime Immuno-Oncology Therapy for Advanced Solid Tumors (GlobeNewswire) +5.53%
May-08-24 12:54PM	INDP Stock Earnings: Indaptus Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
08:00AM	Indaptus Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-11-24 07:30AM	Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting (GlobeNewswire) +9.13%
Mar-28-24 08:00AM	Indaptus Therapeutics to Present at the MedInvest Biotech and Pharma Investor Conference (GlobeNewswire) -10.04%
Mar-25-24 08:30AM	Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual Meeting (GlobeNewswire) +6.90%
Mar-18-24 08:00AM	Indaptus Therapeutics to Participate in Tribe Public Webinar On Wednesday, March 20, 2024 (GlobeNewswire)
Mar-13-24 07:30AM	Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-04-24 07:30AM	Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort (GlobeNewswire) +12.92%
Feb-15-24 08:00AM	Indaptus Therapeutics to Present at the 2024 BIO CEO & Investor Conference (GlobeNewswire)
Feb-08-24 08:00AM	Indaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels (GlobeNewswire)
Jan-04-24 08:00AM	European Patent Office Approves Key Patent for Indaptus Therapeutics' Platform Technology (GlobeNewswire)
Nov-06-23 04:01PM	Indaptus Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) +7.20% -10.07%
08:00AM	Indaptus Therapeutics' Decoy20 Demonstrated a Broad Immune Response of More than Fifty Cytokines and Chemokines in Patients Following a Single Dose in First Cohort of Ongoing Phase 1 Study (GlobeNewswire)
Oct-31-23 09:01AM	Indaptus Therapeutics to Present Positive Pharmacodynamic (PD) Immune and Pharmacokinetic (PK) Results with Patients from First Cohort of Ongoing Phase 1 Study of Decoy20 at Cancer Immunotherapy Meeting (GlobeNewswire)
Sep-27-23 08:00AM	Indaptus Therapeutics to Present at the LD Micro Main Event XVI (GlobeNewswire)
Sep-26-23 08:00AM	Registration Is Now Open For Tribe Publics Webinar Event "Immunotherapy Reimagined" Featuring Indaptus Therapeutics CEO On Friday, September 29, 2023 (GlobeNewswire) +11.65%
Sep-19-23 08:00AM	Indaptus Therapeutics Doses First Patient in Second Cohort of Single Dose Ranging Study of Decoy20 (GlobeNewswire) +7.34%
Sep-06-23 08:05AM	Indaptus Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-14-23 08:00AM	Indaptus Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) +7.83%
Aug-10-23 08:45AM	Indaptus Therapeutics Announces Opening of Next Cohort in Single Dose Ranging Study of Decoy20 (GlobeNewswire) +22.78%
Aug-07-23 08:00AM	Indaptus Therapeutics Appoints Industry Veteran Roger Waltzman, M.D. Chief Medical Officer (GlobeNewswire)
Jun-15-23 08:00AM	Indaptus Therapeutics to Participate in the Maxim Group Virtual Healthcare Conference (GlobeNewswire)
May-31-23 08:30AM	Indaptus Therapeutics to Present at the Jefferies Healthcare Conference 2023 (GlobeNewswire)
May-11-23 07:00AM	Indaptus Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) -9.30%
May-09-23 08:00AM	Following Granting of Indian Patent, Indaptus Therapeutics Achieves Patent Protection in 32 Countries for Decoy Immunotherapy Platform (GlobeNewswire) -16.18%
May-01-23 08:00AM	Indaptus Therapeutics Chief Scientific Officer Michael Newman, Ph.D. Named a Chair of the 4th STING & TLR-Targeting Therapies Summit (GlobeNewswire)
Apr-24-23 09:00AM	Keynotes, Educational Panels and 77 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 25-27, 2023 at the Horseshoe Hotel & Casino in Las Vegas, NV (ACCESSWIRE) -8.74%
Apr-20-23 04:05PM	Indaptus Therapeutics to Present at the Planet MicroCap Showcase: VEGAS 2023 (GlobeNewswire) -7.83%
Apr-19-23 09:28AM	UPDATE -- Indaptus Therapeutics Presents Data Demonstrating Preclinical Efficacy of Decoy, its Bacteria-Based Immunotherapy Platform Technology, at the American Association for Cancer Research Conference 2023 (GlobeNewswire) +23.17%
08:05AM	Indaptus Therapeutics Presents Data Demonstrating Preclinical Efficacy of Decoy, its Bacteria-Based Immunotherapy Platform Technology, at the American Association for Cancer Research Conference 2023 (GlobeNewswire)
Apr-17-23 08:00AM	Indaptus Therapeutics Receives Brazilian Patent Allowance for Decoy Platform (GlobeNewswire)
Mar-22-23 08:00AM	Indaptus Therapeutics to Present at the Investor Summit Conference (GlobeNewswire)
Mar-17-23 08:00AM	Indaptus Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update (GlobeNewswire) +6.34%
Mar-15-23 08:05AM	Indaptus Therapeutics to Present Poster on Its Decoy Anti-Tumor Platform at the American Association for Cancer Research Conference 2023 (GlobeNewswire)
Mar-13-23 08:05AM	Indaptus Therapeutics Activates Emory Winship Cancer Institute as Trial Site in INDP-D101, Its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors (GlobeNewswire)
Mar-07-23 08:05AM	Indaptus Therapeutics Doses First Subject in its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors (GlobeNewswire)
Feb-14-23 08:00AM	Indaptus Therapeutics Names Robert Martell, M.D., Ph.D. to its Board of Directors (GlobeNewswire)
Feb-07-23 08:05AM	Indaptus Therapeutics Activates Morristown Medical Center as Trial Site in INDP-D101, Its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors (GlobeNewswire)
Dec-13-22 07:30AM	Indaptus Therapeutics Announces Initiation of First-In-Human, Open Label, Dose Escalation and Expansion Multicenter Phase 1 Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors (GlobeNewswire) +9.52%
Nov-10-22 04:05PM	Indaptus Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire) +16.18%
Oct-18-22 07:00AM	Indaptus Therapeutics to Present at the LD Micro Main Event XV (GlobeNewswire)
Sep-06-22 09:02AM	Indaptus Therapeutics to Present at the 24th Annual H.C. Wainwright Global Investment Conference (GlobeNewswire)
Aug-08-22 08:00AM	Indaptus Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Jun-09-22 07:00AM	Indaptus Therapeutics to Present at JMP Securities Life Sciences Conference (GlobeNewswire)
Jun-03-22 07:00AM	Indaptus Therapeutics to Present at Jefferies Healthcare Conference (GlobeNewswire)
May-23-22 08:00AM	Enlivex Appoints Dr. Roger J. Pomerantz to its Board of Directors as Vice Chairman (GlobeNewswire)
May-19-22 07:00AM	Indaptus Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Decoy20 in Solid Tumors (GlobeNewswire) +18.80%
May-18-22 04:15PM	Indaptus Therapeutics to Present at H.C. Wainwright Global Investment Conference (GlobeNewswire)
May-12-22 08:00AM	Indaptus Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
May-03-22 12:20PM	Indaptus Therapeutics, Inc. (NASDAQ:INDP) insiders placed bullish bets worth US$2.4m in the last 12 months (Simply Wall St.)
Apr-20-22 07:00AM	Indaptus Therapeutics to Present at 2nd Annual Chronic HBV Drug Development Summit (GlobeNewswire)
Mar-23-22 07:00AM	Indaptus Therapeutics to Present at Maxim Group 2022 Virtual Growth Conference (GlobeNewswire)
Mar-21-22 07:00AM	Indaptus Therapeutics Reports Fourth Quarter and Year End 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-17-22 07:00AM	Indaptus Therapeutics to Present at 3rd Annual STING & TLR-Targeting Therapies Summit (GlobeNewswire) +6.73%
Mar-07-22 07:00AM	Indaptus Therapeutics to Present at 34th Annual ROTH Conference (GlobeNewswire) -7.67%
Jan-14-22 09:38AM	Stratos Wealth Partners, LTD. Buys PowerShares QQQ Trust Ser 1, WisdomTree U.S. ... (GuruFocus.com)
Jan-05-22 07:00AM	Indaptus Therapeutics to Present at H.C. Wainwright BioConnect 2022 Virtual Conference (GlobeNewswire) -8.55%

Indaptus Therapeutics, Inc. is a clinical biotechnology company. The firm engages in the development of a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It created patented treatment methods and associated patented compositions for attenuation and killing of non-pathogenic, Gram-negative bacteria. The company was founded by Michael James Newman on February 24, 2021 and is headquartered in New York, NY.

FounderDr. Michael J. Newman Ph.D.

Chief Operating OfficerMr. Walt Addison Linscott Esq.

CEO & ChairmanMr. Junyi Dai

Chief Financial OfficerMr. Yu Ding

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

INDP

Indaptus Therapeutics Inc

Upgrade your Finviz experience